No Prescription |
 |
 | ||
|
LOPIMUNE Kaletra |
|
| ||
No Prescription » Prescription Drugs 10 » LOPIMUNE Kaletra This combination product contains two medications lopinavir and ritonavir. This product is used in combination with other medications to help control your HIV infection thereby improving your quality of life. It also lowers your risk of getting HIV disease complications (e.g. opportunistic infections cancer). Both lopinavir and ritonavir belong to a class of drugs known as HIV protease inhibitors. The ritonavir in this product helps the lopinavir to stay in your body. This effect builds up the amount of lopinavir in your body increasing its effectiveness.This lopinavir/ritonavir product is not a cure for HIV infection and it does not prevent the spread of HIV to others through sexual contact or blood contamination (e.g. sharing used needles).How to use Lopinavir-Ritonavir OralRead the Patient Information Leaflet provided by your pharmacist before you start using lopinavir/ritonavir and each time you get a refill. If you have any questions regarding the information consult your doctor or pharmacist.Take this product by mouth with or without food usually once or twice daily or as directed by your doctor. Swallow the tablets whole. Do not crush break or chew the tablets.Dosage is based on your medical condition response to therapy and any other anti-HIV medications you may be taking.Taking this product once a day is not recommended if you have previously taken other drugs to treat your HIV infection. Consult your doctor for more details.If you are taking didanosine in addition to this product you can take it at the same time as this product but take them both without food.It is very important to continue taking this medication (and other anti-HIV medications) exactly as prescribed by your doctor.This medication works best when the amount of drug in your body is kept at a constant level. Therefore take this drug at evenly spaced intervals. Remember to use it at the same time(s) each day. Do not skip any doses.Do not take more or less of this drug than prescribed or stop taking it (or other HIV medicines) even for a short time unless directed to do so by your doctor. Skipping or changing your dose without approval from your doctor may cause the amount of virus to increase make the infection more difficult to treat (resistant) or worsen side effects.Lopinavir-Ritonavir Oral is used to treat the following:HIVLopinavir-Ritonavir Oral may also be used to treat:Prevention of HIV Infection after Exposure Buy LOPIMUNE Kaletra and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LOPIMUNE Kaletra: Product Type: Prescription Drugs 10 LOPIMUNE ( Kaletra Generic LOPINAVIR/RITONAVIR ) LOPIMUNE (Kaletra Generic LOPINAVIR/RITONAVIR) Kaletra Generic LOPINAVIR/RITONAVIR 200/50MG Kaletra Generic LOPINAVIR/RITONAVIR LOPIMUNE
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
